Search
Palisade Bio Inc
PALIAdd to Watchlist
2.100USD
+0.130+6.60%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
334.83MMarket Cap
17.83P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+6.60%
5 Days
+11.11%
1 Month
+8.81%
6 Months
-16.00%
Year to Date
-10.64%
1 Year
+189.66%
Key Figures
2.010Open
2.110High
3.35MVolume
17.83P/E TTM
LossP/E Dynamic
--Dividend TTM
2.10%Turnover Ratio
1.970Prev. Close
1.960Low
4.89MTurnover
LossP/E Static
2.59P/B
0.00%Div Yield TTM
-34.13%ROA
2.85552wk High
0.60Volume Ratio
-14.44MNet Profit
159.44MShares
0.1178EPS TTM
1.53Beta
-36.40%ROE
0.53052wk Low
7.61%Amplitude
100.00%Gross Margin
334.83MMarket Cap
0.28Reward/Risk
7.35%Risk Rate
TradingKey Stock Score of Palisade Bio Inc
Currency: USD Updated: 2026-07-02Key Insights
Palisade Bio Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 96 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.67.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Palisade Bio Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Palisade Bio Inc Highlights
StrengthsRisks
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is 17.83, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 138.32M shares, increasing 34.40% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 348.12K shares of this stock.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
10.667
Target Price
+441.46%
Upside Space
Palisade Bio Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Palisade Bio Inc Info
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
Ticker SymbolPALI
CompanyPalisade Bio Inc
CEOFinley (J. D.)
Websitehttps://palisadebio.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Palisade Bio Inc (PALI)?
The current price of Palisade Bio Inc (PALI) is 2.10.
What is the symbol of Palisade Bio Inc?
The ticker symbol of Palisade Bio Inc is PALI.
What is the 52-week high of Palisade Bio Inc?
The 52-week high of Palisade Bio Inc is 2.85.
What is the 52-week low of Palisade Bio Inc?
The 52-week low of Palisade Bio Inc is 0.53.
What is the market capitalization of Palisade Bio Inc?
The market capitalization of Palisade Bio Inc is 334.83M.
Is Palisade Bio Inc (PALI) currently rated as Buy, Hold, or Sell?
According to analysts, Palisade Bio Inc (PALI) has an overall rating of Buy, with a price target of 10.67.
What is the Earnings Per Share (EPS TTM) of Palisade Bio Inc (PALI)?
The Earnings Per Share (EPS TTM) of Palisade Bio Inc (PALI) is -0.30.